BIOCRYST PHARMACEUTICALS, INC. Liabilities Subject to Compromise, Early Contract Termination Fees
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Liabilities Subject to Compromise, Early Contract Termination Fees of $10.00 million as of 2012-09-30, per its 10-Q filed 2012-11-08.
Discontinued › Notes
us-gaap:LiabilitiesSubjectToCompromiseEarlyContractTerminationFees · last filed 2012-11-08
- 2012-09-30: Liabilities Subject to Compromise, Early Contract Termination Fees $10.00M.
| Period end | Liabilities Subject to Compromise, Early Contract Termination Fees |
|---|---|
| 2012-09-30 | $10.00M 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |